Cancer Treatments Linked to Aggravated Insomnia
the Cancer Therapy Advisor take:
Insomnia symptoms become intensified by cancer treatments and their side effects, according to a study published online in the journal Cancer.
In a longitudinal study involving 465 patients with breast cancer and 263 patients with prostate cancer, Insomnia Severity Index (ISI) and somatic symptoms were assessed at baseline and 2, 6, 10, 14, and 18 months later.
Results showed that patients with breast cancer who underwent radiotherapy and chemotherapy experienced an increased insomnia severity, but those who underwent hormone therapy did not. In patients with prostate cancer, androgen deprivation therapy was also associated with increased insomnia.
A variety of somatic symptoms were found to significantly mediate the effects of chemotherapy and radiotherapy on insomnia in patients with breast cancer.
Furthermore, night sweats were determined to have a significant mediating role for hormone therapy in patients with breast cancer and patients with prostate cancer.
The study suggests that side effects of cancer treatments be more closely monitored and managed in order to prevent the aggravation of insomnia symptoms in patients.
Insomnia symptoms become intensified by cancer treatments and their side effects.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- FDA Grants Priority Review to Afatinib for Uncommon EGFR-positive NSCLC
- Custirsen May Not Improve Survival in Castration-resistant Prostate Cancer
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC
- Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC